Medicenna Therapeutics Corp Stock Cash Flow From Operations
| MDNA Stock | CAD 1.72 0.10 6.17% |
Medicenna Therapeutics Corp fundamentals help investors to digest information that contributes to Medicenna Therapeutics' financial success or failures. It also enables traders to predict the movement of Medicenna Stock. The fundamental analysis module provides a way to measure Medicenna Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medicenna Therapeutics stock.
Medicenna | Cash Flow From Operations |
Medicenna Therapeutics Corp Company Cash Flow From Operations Analysis
Medicenna Therapeutics' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Medicenna Therapeutics Cash Flow From Operations | (16.26 M) |
Most of Medicenna Therapeutics' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medicenna Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Medicenna Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Medicenna Therapeutics is extremely important. It helps to project a fair market value of Medicenna Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Medicenna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Medicenna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Medicenna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Medicenna Therapeutics Corp has (16.26 Million) in Cash Flow From Operations. This is 103.08% lower than that of the Biotechnology sector and 126.01% lower than that of the Health Care industry. The cash flow from operations for all Canada stocks is 101.67% higher than that of the company.
Medicenna Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medicenna Therapeutics' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medicenna Therapeutics could also be used in its relative valuation, which is a method of valuing Medicenna Therapeutics by comparing valuation metrics of similar companies.Medicenna Therapeutics is currently under evaluation in cash flow from operations category among its peers.
Medicenna Fundamentals
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 96.37 M | ||||
| Shares Outstanding | 78.16 M | ||||
| Shares Owned By Insiders | 22.07 % | ||||
| Shares Owned By Institutions | 12.77 % | ||||
| Number Of Shares Shorted | 33.71 K | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (18.67 M) | ||||
| Net Income | (25.47 M) | ||||
| Cash And Equivalents | 33.6 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 13.94 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 26.75 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (16.26 M) | ||||
| Short Ratio | 0.55 X | ||||
| Earnings Per Share | (0.38) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 16 | ||||
| Beta | 1.19 | ||||
| Market Capitalization | 134.43 M | ||||
| Total Asset | 19.13 M | ||||
| Retained Earnings | (106.45 M) | ||||
| Working Capital | 16.21 M | ||||
| Net Asset | 19.13 M |
About Medicenna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medicenna Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicenna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicenna Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medicenna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Medicenna Stock
| 0.56 | AMZN | Amazon CDR | PairCorr |
| 0.55 | BOFA | Bank of America | PairCorr |
| 0.48 | JPM | JPMorgan Chase | PairCorr |
| 0.41 | BRK | Berkshire Hathaway CDR | PairCorr |
| 0.32 | TD-PFD | Toronto Dominion Bank Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.
The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medicenna Stock
Medicenna Therapeutics financial ratios help investors to determine whether Medicenna Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicenna with respect to the benefits of owning Medicenna Therapeutics security.